Tag: IXC

Invex Therapeutics ASX IXC Idiopathic Intracranial Hypertension headache

Invex Therapeutics raises $26 million as it plans for Phase 3 clinical trial

Two days since publishing its Phase 2 clinical trial results and announcing “clear evidence” that its Exeatide drug is effective at reducing intracranial pressure in Idiopathic Intracranial Hypertensi...
Invex Therapeutics ASX IXC repurpose diabetic drug brain disorders Exenatide IPO

Invex Therapeutics aims to repurpose a diabetic drug for brain disorders

Biopharmaceutical company Invex Therapeutics is planning to make its ASX debut this week under the ticker code “IXC” with ambitions to repurpose an approved diabetes drug for some neurological conditi...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS